Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
NCT04067336Phase 2Active, not recruiting
- Sponsor
- Kura Oncology
- Start
- Sep 2019
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label trial of ziftomenib in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) (7 arms), sponsored by Kura Oncology. Primary endpoints: Maximum Tolerated Dose at 28 days, Recommended Phase 2 Dose at 28 days and 10 more. Started Sep 2019; status: active, not recruiting.
02
Drugs
ziftomenib
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT04067336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04067336.